BMS-1001

SKU: orb1298907

Description

BMS-1001 is a high-affinity small molecule inhibitor that potently blocks the PD-1/PD-L1 immune checkpoint interaction, demonstrating an IC50 of 2.25 nM. This inhibitor is a valuable tool for investigating cancer immunotherapy mechanisms in both biochemical and cellular assays, supporting research in oncology and immunology.

Research Area

Cell Biology, Immunology & Inflammation

Key Properties

• CAS Number: 2113650-03-4
• MW: 594.7
• Purity: 98.89% (May vary between batches)
• Formula: C₃₅H₃₄N₂O₇
• SMILES: CC1=CC(CN[C@H](CO)C(O)=O)=C(OCC2=CC(=CC=C2)C#N)C=C1OCC1=C(C)C(=CC=C1)C1=CC2=C(OCCO2)C=C1
• Target: PD-1/PD-L1
• Solubility: DMSO:5.95 mg/mL (10.01 mM)

Bioactivity

• In Vitro:
  The small-molecule inhibitors of the PD-1/PD-L1 interaction, BMS-1001 , bind to human PD-L1 and block its interaction with PD-1, when tested on isolated proteins. The compounds present low toxicity towards tested cell lines and block the interaction of soluble PD-L1 with the cell surface-expressed PD-1. BMS-1001 alleviate the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes. Moreover, the compounds were effective in attenuating the inhibitory effect of the cell surface-associated PD-L1.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

BMS1001, BMS-1001, BMS 1001, PD-1/PD-L1, PD1/PDL1, PD1, PD-1, PD-L1, PDL1

Compound Identifiers

PubChem CID

131839624